| Trudylee F Chandler, AGACNP-BC | |
|
3443 Dickerson Pike Ste 680, Nashville, TN 37207-2537 | |
| (615) 865-3322 | |
| (615) 467-6692 |
| Full Name | Trudylee F Chandler |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 3443 Dickerson Pike Ste 680, Nashville, Tennessee |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366089161 | NPI | - | NPPES |
| Entity Name | Crossroads Urgent Care Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366644361 PECOS PAC ID: 8325117484 Enrollment ID: O20080515000672 |
News Archive
In a study published on Monday in the Lancet Infectious Diseases, researchers from the Centers for Disease Control and Prevention (CDC) said the 2009 H1N1 swine flu pandemic likely killed about 284,500 people worldwide between August 2009 and August 2010, a number 15 times higher than the 18,500 deaths reported to the WHO, Bloomberg News reports.
Catasys, Inc., a provider of proprietary big-data based analytics and predictive modeling driven health management services for health plans, announced today that it has signed a national agreement with Humana Behavioral Health to combine its substance abuse care management with Humana clinical programs to address the needs of members experiencing substance abuse challenges.
Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, will present data from three Phase II clinical trials highlighting the clinical potential of its unique phosphatidylserine -targeting antibody bavituximab for the treatment of solid tumors.
Scientists found that those who were exposed to phthalates, colourless man-made substances included in a variety of common consumer products, were more prone to weight gain. And subjects with even 'modest' levels of the substance in their bloodstream were twice as likely to develop diabetes.
BioClinica™, Inc., (NASDAQ: BIOC), a global provider of clinical trial services, today announced it will be hosting a seminar on November 18, 2009 highlighting new research, trends and updates from industry experts in rheumatoid arthritis. This event, which will be held in Lafayette, PA, is part of the continuing series of symposia hosted by the company for pharmaceutical and medical imaging executives over the past four years that addresses the challenges and approaches in conducting clinical trials.
› Verified 6 days ago
| Entity Name | App Of Tennessee Hm, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396160768 PECOS PAC ID: 5395960694 Enrollment ID: O20140630001088 |
News Archive
In a study published on Monday in the Lancet Infectious Diseases, researchers from the Centers for Disease Control and Prevention (CDC) said the 2009 H1N1 swine flu pandemic likely killed about 284,500 people worldwide between August 2009 and August 2010, a number 15 times higher than the 18,500 deaths reported to the WHO, Bloomberg News reports.
Catasys, Inc., a provider of proprietary big-data based analytics and predictive modeling driven health management services for health plans, announced today that it has signed a national agreement with Humana Behavioral Health to combine its substance abuse care management with Humana clinical programs to address the needs of members experiencing substance abuse challenges.
Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, will present data from three Phase II clinical trials highlighting the clinical potential of its unique phosphatidylserine -targeting antibody bavituximab for the treatment of solid tumors.
Scientists found that those who were exposed to phthalates, colourless man-made substances included in a variety of common consumer products, were more prone to weight gain. And subjects with even 'modest' levels of the substance in their bloodstream were twice as likely to develop diabetes.
BioClinica™, Inc., (NASDAQ: BIOC), a global provider of clinical trial services, today announced it will be hosting a seminar on November 18, 2009 highlighting new research, trends and updates from industry experts in rheumatoid arthritis. This event, which will be held in Lafayette, PA, is part of the continuing series of symposia hosted by the company for pharmaceutical and medical imaging executives over the past four years that addresses the challenges and approaches in conducting clinical trials.
› Verified 6 days ago
| Entity Name | Novus Behavioral Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770078040 PECOS PAC ID: 3173854759 Enrollment ID: O20191011002464 |
News Archive
In a study published on Monday in the Lancet Infectious Diseases, researchers from the Centers for Disease Control and Prevention (CDC) said the 2009 H1N1 swine flu pandemic likely killed about 284,500 people worldwide between August 2009 and August 2010, a number 15 times higher than the 18,500 deaths reported to the WHO, Bloomberg News reports.
Catasys, Inc., a provider of proprietary big-data based analytics and predictive modeling driven health management services for health plans, announced today that it has signed a national agreement with Humana Behavioral Health to combine its substance abuse care management with Humana clinical programs to address the needs of members experiencing substance abuse challenges.
Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, will present data from three Phase II clinical trials highlighting the clinical potential of its unique phosphatidylserine -targeting antibody bavituximab for the treatment of solid tumors.
Scientists found that those who were exposed to phthalates, colourless man-made substances included in a variety of common consumer products, were more prone to weight gain. And subjects with even 'modest' levels of the substance in their bloodstream were twice as likely to develop diabetes.
BioClinica™, Inc., (NASDAQ: BIOC), a global provider of clinical trial services, today announced it will be hosting a seminar on November 18, 2009 highlighting new research, trends and updates from industry experts in rheumatoid arthritis. This event, which will be held in Lafayette, PA, is part of the continuing series of symposia hosted by the company for pharmaceutical and medical imaging executives over the past four years that addresses the challenges and approaches in conducting clinical trials.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Trudylee F Chandler, AGACNP-BC 3443 Dickerson Pike Ste 680, Nashville, TN 37207-2537 Ph: (615) 865-3322 | Trudylee F Chandler, AGACNP-BC 3443 Dickerson Pike Ste 680, Nashville, TN 37207-2537 Ph: (615) 865-3322 |
News Archive
In a study published on Monday in the Lancet Infectious Diseases, researchers from the Centers for Disease Control and Prevention (CDC) said the 2009 H1N1 swine flu pandemic likely killed about 284,500 people worldwide between August 2009 and August 2010, a number 15 times higher than the 18,500 deaths reported to the WHO, Bloomberg News reports.
Catasys, Inc., a provider of proprietary big-data based analytics and predictive modeling driven health management services for health plans, announced today that it has signed a national agreement with Humana Behavioral Health to combine its substance abuse care management with Humana clinical programs to address the needs of members experiencing substance abuse challenges.
Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, will present data from three Phase II clinical trials highlighting the clinical potential of its unique phosphatidylserine -targeting antibody bavituximab for the treatment of solid tumors.
Scientists found that those who were exposed to phthalates, colourless man-made substances included in a variety of common consumer products, were more prone to weight gain. And subjects with even 'modest' levels of the substance in their bloodstream were twice as likely to develop diabetes.
BioClinica™, Inc., (NASDAQ: BIOC), a global provider of clinical trial services, today announced it will be hosting a seminar on November 18, 2009 highlighting new research, trends and updates from industry experts in rheumatoid arthritis. This event, which will be held in Lafayette, PA, is part of the continuing series of symposia hosted by the company for pharmaceutical and medical imaging executives over the past four years that addresses the challenges and approaches in conducting clinical trials.
› Verified 6 days ago